Astrocytes and Free Radicals: New target Identified in Fight Against dementia
Table of Contents
A groundbreaking study published November 4 in nature Metabolism reveals a surprising contributor to dementia: free radicals originating not from neurons, but from astrocytes, a type of brain support cell. Researchers at Weill Cornell Medicine have demonstrated that blocking this specific source of damaging molecules reduces inflammation and protects neurons, offering a promising new avenue for treating neurodegenerative diseases like frontotemporal dementia and AlzheimerS disease.
The research team, led by Dr. Anna Orr and Dr.Adam Orr, expressed excitement about the potential for translating these findings into effective therapies. “We can now target specific mechanisms and go after the exact sites that are relevant for disease,” Dr. Anna Orr stated.
The Role of Mitochondria and Free Radicals in brain Health
At the heart of this finding lies the understanding of reactive oxygen species (ROS), commonly known as free radicals.While ROS play a role in normal cellular function, an overabundance can lead to oxidative stress and damage to cells. Previous attempts to combat neurodegeneration wiht broad-spectrum antioxidants have yielded disappointing results. “That lack of success might be related to the inability of antioxidants to block ROS at their source and do so selectively without altering cell metabolism,” Dr. Adam Orr noted.
A Novel Approach: Targeting ROS at the Source
Dr. Orr, during postdoctoral work, pioneered a drug discovery platform focused on identifying molecules that could suppress ROS production at specific mitochondrial sites without disrupting normal cellular processes. This led to the identification of a class of compounds called S3QELs (“sequels”), which demonstrated the ability to block harmful ROS activity.
The team’s inquiry centered on Complex III, a component of mitochondria known to generate ROS that can leak into surrounding cells, possibly causing damage. Surprisingly, the source of excess ROS wasn’t neurons themselves, but rather astrocytes – cells that provide crucial structural and metabolic support to neurons.
“When we added S3QELs, we found significant neuronal protection but only in the presence of astrocytes,” said Daniel Barnett, a graduate student in the Orr lab and the study’s lead author. “This suggested that ROS coming from Complex III caused at least some of the neuronal pathology.”
Further experimentation revealed that when astrocytes were exposed to factors associated with dementia, such as inflammatory molecules and amyloid-beta proteins, their mitochondrial ROS production increased dramatically. Treatment with S3QELs effectively suppressed this surge,while blocking other ROS sources proved less effective. Barnett’s research also showed that ROS oxidized key immune and metabolic proteins, disrupting the activity of thousands of genes linked to inflammation and dementia.
“The precision of these mechanisms had not been previously appreciated, especially not in brain cells,” Dr. Anna Orr emphasized. “This suggests a very nuanced process in which specific triggers induce ROS from specific mitochondrial sites to affect specific targets.”
Promising Results in Animal Models
When the S3QEL compound was administered to mice engineered to model frontotemporal dementia, researchers observed a reduction in astrocyte activation, decreased levels of inflammatory gene expression, and a lessening of a tau modification associated with dementia. notably, these positive effects were observed even when treatment commenced after symptoms had already appeared.
Extended treatment demonstrated a favorable safety profile, improving lifespan without causing significant side effects. Dr. Anna Orr attributed this to the compound’s highly targeted action.
The team is now collaborating with medicinal chemist Dr.Subhash Sinha to further develop the S3QEL compounds. Future research will also explore the influence of disease-associated genes on ROS production and whether genetic variations impacting dementia risk are linked to altered mitochondrial ROS activity. .
A Paradigm Shift in Understanding Free radicals
“The study has really changed our thinking about free radicals and opened up many new avenues of investigation,” Dr. Adam Orr concluded. The potential of these findings to revolutionize approaches to inflammation and neurodegeneration is highlighted in the Nature Metabolism publication, signaling a significant step forward in the ongoing quest to combat devastating neurological diseases.
